HRT reanalyses shows favorable risk-benefit profile with recommended treatment strategies
August 26th 2011The risk-benefit ratio is in favor of hormone replacement therapy (HRT) when initiated near menopause, according to new consensus statements issued by The North American Menopause Society, The American Menopause Society and the International Menopause Society and published in a recent paper in the July issue of Women?s Health.
Read More
US healthcare system among least cost-effective in reducing mortality
August 26th 2011The United States healthcare system is one of the least cost-effective in reducing mortality rates; while the United Kingdom is among the most cost-effective, according to a recent study published in the July issue of Journal of the Royal Society of Medicine Short Reports.
Read More
Once-daily rivaroxaban appears to be as effective as dose-adjusted warfarin
August 26th 2011Once-daily oral rivaroxaban (Xarelto, Bayer), a direct factor Xa inhibitor, appears to be as effective as dose-adjusted warfarin in preventing stroke or major embolism in patients with nonvalvular atrial fibrillation, according to a study published online August 10 in the New England Journal of Medicine.
Read More
Children's dose-dependent CA-MRSA risk increases with antibacterial use
August 26th 2011Antibacterial drug use in children is associated with a dose-dependant increased risk of acquiring community-associated methicillin-resistant Staphylococcus aureus (Ca-MRSA), according to the results of a population-based, case-control study reported online August 1 in the Archives of Pediatrics & Adolescent Medicine.
Read More
FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer
August 19th 2011FDA has approved vemurafenib (Zelboraf, Genentech), the second melanoma drug this year to improve overall survival. Zelboraf is indicated for the treatment of patients with late-stage (metastatic) or unresectable melanoma, the most dangerous type of skin cancer.
Read More
FDA approves single-tablet regimen for HIV-1 infection in treatment-naïve adults
August 19th 2011FDA has approved emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Complera, Gilead Sciences), a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.
Read More
FDA approves first antivenom for Centruroides scorpion stings
August 19th 2011FDA has approved the first antivenom treatment specifically for a scorpion sting by the Centruroides scorpions in the United States. The new biologic treatment?called Anascorp?was designated an orphan drug and given priority review because adequate treatment did not exist in the United States, according to a consumer update and corresponding news release issued by the agency.
Read More
New guidelines for COPD diagnosis, management
August 19th 2011The American College of Physicians (ACP), American College of Chest Physicians (ACCP), American Thoracic Society (ACT), and the European Respiratory Society (ERS) have issued updated recommendations to the 2007 ACP clinical practice guideline on diagnosis and management of stable chronic obstructive pulmonary disease (COPD). The new recommendations were published in Annals of Internal Medicine.
Read More
FDA warns unapproved emergency birth control may be ineffective, unsafe
August 19th 2011FDA is warning consumers in the United States not to use an emergency birth control medicine labeled as Evital. According to a recent press release from the agency, Evital has not been approved by FDA, and the product may be a counterfeit version of the morning-after pill. It may not be safe or effective in preventing pregnancy.
Read More
Medicare Part D reduces nondrug medical spending
August 15th 2011?Implementation of Medicare Part D and Nondrug Medical Spending for Elderly Adults With Limited Prior Drug Coverage? report finds that Part D implementation reduces nondrug medical spending for Medicare beneficiaries with limited prior drug coverage.
Read More
Health insurance plans to cover birth control at 100%
August 15th 2011New guidelines announced by the U.S. Department of Health and Human Services (HHS) require new health insurance plans to cover women?s preventive services such as well-woman visits, breastfeeding support, domestic violence screening, and contraception without charging a co-payment, co-insurance or a deductible
Read More